Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options for 30,400 shares to four new employees. The options are priced at $28.24 per share, equivalent to the closing price on August 9, 2021. This issuance falls under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies, with five molecules currently in clinical development targeting various oncology indications.

Arcus Biosciences (NYSE:RCUS) reported its Q2 2021 financial results, showing significant advancements in its oncology portfolio. The company ended June with cash and investments of $805.1 million, an increase from $735.1 million in December 2020, primarily due to a $220.4 million stock placement with Gilead. Collaboration revenues surged to $9.5 million, compared to $1.8 million a year earlier. However, the net loss rose to $76 million in Q2 2021, up from $45.1 million in Q2 2020, indicating increased operational costs.

Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on oncology, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on August 11, 2021, at 1:45 p.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks post-event. Arcus is advancing five clinical molecules, including Etrumadenant (AB928) and AB680, targeting multiple cancers. The company's innovative approaches aim to address significant unmet medical needs in cancer therapy.

Arcus Biosciences (NYSE:RCUS) will report its financial results for Q2 2021 on August 5, 2021, after market close. A conference call to discuss these results and corporate highlights will begin at 1:30 PM PT/4:30 PM ET. Investors can join via phone or listen to a live webcast on the company's website. Arcus is advancing five molecules in clinical development, including Etrumadenant and AB680, targeting various cancers with promising therapies aimed at addressing unmet medical needs.

Arcus Biosciences (NYSE:RCUS) announced the grant of stock options for 72,800 shares to six new employees at an exercise price of $32.85, corresponding to the closing price on July 23, 2021. This grant is made under the Company’s 2020 Inducement Plan, approved by its Board of Directors. Arcus focuses on developing innovative cancer therapies and has five molecules in clinical development, including Etrumadenant and Domvanalimab, targeting significant unmet needs in various cancers. The company aims to advance its portfolio through clinical trials and collaborations.

Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Board's Compensation Committee granted options to purchase 77,800 shares to seven new employees at an exercise price of $28.75, the closing price on July 8, 2021. This grant is part of the 2020 Inducement Plan, approved under NYSE rules. Arcus focuses on developing innovative cancer therapies with five molecules in clinical stages, including Etrumadenant for various cancers and AB680 for metastatic pancreatic cancer.

Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to ten new employees, totaling 141,800 shares at an exercise price of $23.40, based on the closing price from June 23, 2021. This issuance is part of the Company’s 2020 Inducement Plan approved by the Board. Arcus is focused on developing innovative cancer therapies, with five molecules currently in clinical trials, including the promising Etrumadenant and Domvanalimab, aimed at addressing significant unmet needs in oncology.

Arcus Biosciences (NYSE:RCUS) announced promising results from the interim analysis of the Phase 2 ARC-7 study involving domvanalimab-based combinations for treating metastatic, PD-L1≥50% non-small cell lung cancer (NSCLC). Both combination arms exhibited encouraging clinical activity. The monotherapy arm of zimberelimab displayed response rates comparable to existing anti-PD-1 therapies. No unexpected safety concerns were noted. Arcus and partner Gilead Sciences are set to further explore Phase 3 studies. Upcoming data from ARC-7 will be submitted for presentation at a medical conference.

Arcus Biosciences (NYSE:RCUS) granted stock options to ten new employees, allowing them to purchase a total of 115,800 shares at $24.76 per share, the closing price on June 8, 2021. This grant is part of the Company’s 2020 Inducement Plan approved in January 2020. Arcus is focused on developing cancer therapies, with five molecules in clinical development, including Etrumadenant, AB680, and Domvanalimab, targeting various cancers. The Company's ongoing trials aim to address significant unmet needs in oncology.